Fate Therapeutics Inc FATE
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-10-01 |
| Shares Out. | 116,560,000 |
| Website | fatetherapeutics.com/ ↗ |
| Phone | 13026365400 |
| Employees | 161 |
| Revenue | $1.3M |
| Gross Profit | $1.3M |
| Net Income | -$31.2M |
| Free Cash Flow | -$108.1M |
| Total Assets | $284.9M |
| Total Liabilities | $104.8M |
| Equity | $179.7M |
About Fate Therapeutics Inc
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Fate Therapeutics Inc is a publicly traded company under the ticker symbol FATE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)